Allison Wey, VP of IR for Durata Therapeutics through its acquisition by Actavis, has moved to Regulus Therapeutics as VP of IR and corporate communications.
COO Jay Hagan said Wey's experience will be valuable as the publicly traded company's pipeline matures. Regulus is focused on microRNA therapeutics and developing treatments for chronic hepatitis C virus and Alport syndrome, among others.
Earlier, she was VP of IR and corporate affairs at Par Pharmaceuticals, departing on its acquisition by TPG. She was also VP of IR for Boren.
On the agency side, Wey was a senior VP at Edelman Financial and managing director for financial communications at Hill+Knowlton Strategies after starting out in finance.
The pressure is on PR pros to make sure corporate messaging remains clear and cohesive. Business jargon is an obstacle to achieving this goal.
In today's volatile world of constant disruption, the ability to offer reliability and dependability is more valuable than ever.
